Sanofi (NYSE:SNY) and GlaxoSmithKline (NYSE:GSK) have teamed up on a COVID-19 vaccine candidate that uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
The companies launched a Phase 1/2 study on September 3 with 440 subjects and expect the first results in early December 2020. They plan to start a pivotal Phase 3 study before the end of the year and line it up for a regulatory approval request in the first half of 2021.
Both companies have vaccine manufacturing sites in Canada that will contribute to the vaccine production there and elsewhere, as they landed a $2.1 billion contract from the Trump administration for the vaccine candidate in July. The Canadian government contracted this week to receive up to 72 million doses of the Sanofi/GSK COVID-19 vaccine beginning in 2021.